NattoPharma, producer of MenaQ7® vitamin K2 ingredients, announced that the company has signed a new and long-term research agreement with the Cardiovascular Research Institute Maastricht, (CARIM), and University of Maastricht, Netherlands. This agreement provides NattoPharma with the ability to evaluate new vitamin K2 technologies, create proof of concept studies for novel delivery systems and evaluate the impact of vitamin K2 on human health.
NattoPharma and CARIM recently successfully applied and received a grant from the Dutch government to investigate effects of vitamin K supplementation on cardiovascular health.
“This achievement confirms the success of NattoPharma's strategy to secure a substantial part of our product development and innovation project costs through public funding, grants and in collaboration with high-level scientific institutions," said Frode M. Bohan, chairman of the board of NattoPharma.
Dr. Leon Schurgers of CARIM states, “The agreement with NattoPharma will strengthen our seminal research to understand the essential vitamin K2 and its pivotal contribution to healthy aging."
NattoPharma already collaborates with VitaK at the University of Maastricht. In this collaboration the recently published three-year study demonstrated bone health and bone strength benefits of MenaQ7 Vitamin K2 in healthy post-menopausal women, published in the journal Osteoporosis International. The new agreement with CARIM complements and expands NattoPharma’s R&D efforts.
“Through the agreement with CARIM, NattoPharma continues the efforts to explore biological vitamin K2 effects,” said Hogne Vik, CEO. “With this agreement NattoPharma will consolidate our position as the dominating vitamin K2 company conducting therapeutic human clinical research to validate vitamin K2’s benefits.”